![](https://i.imgur.com/CLvY2jA.png")
25-09-2021, 04:40 PM
https://www.forbes.com/sites/siladityara...b9ef5622b6
People who were inoculated with the Pfizer-BioNTech Covid-19 vaccine had ten times the amount of antibodies compared to those who had received the Chinese-developed Sinovac vaccine, a Hong Kong study has shown, likely offering evidence about the varying levels of protection offered by different Covid jabs
According to the study published in The Lancet, the difference in concentrations of neutralizing antibodies “could translate into substantial differences in vaccine effectiveness.”
The study was based on samples collected from 1,442 healthcare workers working in medical clinics, public and private hospitals in Hong Kong.
The recipients of the Sinovac had “similar or lower” levels of antibodies compared to patients who had been infected by Covid-19 and had managed to fight off the disease, AFP reported.
The study only looked at concentrations of neutralizing antibodies—which are not the only measure of a vaccine’s effectiveness—and did not include any data on T cells and other potential markers of protection.
The Hong Kong study and other research from around the world suggest that vaccines using the mRNA technology—like Pfizer and Moderna—may offer more robust protection against the coronavirus and its variants compared to the more traditional inactivated virus shots. However, these viral vector vaccines are considered a critical tool for vaccinating most of the world are they are both cheaper and easier to produce and store.
People who were inoculated with the Pfizer-BioNTech Covid-19 vaccine had ten times the amount of antibodies compared to those who had received the Chinese-developed Sinovac vaccine, a Hong Kong study has shown, likely offering evidence about the varying levels of protection offered by different Covid jabs
According to the study published in The Lancet, the difference in concentrations of neutralizing antibodies “could translate into substantial differences in vaccine effectiveness.”
The study was based on samples collected from 1,442 healthcare workers working in medical clinics, public and private hospitals in Hong Kong.
The recipients of the Sinovac had “similar or lower” levels of antibodies compared to patients who had been infected by Covid-19 and had managed to fight off the disease, AFP reported.
The study only looked at concentrations of neutralizing antibodies—which are not the only measure of a vaccine’s effectiveness—and did not include any data on T cells and other potential markers of protection.
The Hong Kong study and other research from around the world suggest that vaccines using the mRNA technology—like Pfizer and Moderna—may offer more robust protection against the coronavirus and its variants compared to the more traditional inactivated virus shots. However, these viral vector vaccines are considered a critical tool for vaccinating most of the world are they are both cheaper and easier to produce and store.
